한국어
Privacy Policy
Asia Economy. (November 23, 2022)
HAII Raises 7.5 Billion Won in Series B Funding
HAII successfully secured 7.5 billion won in Series B funding, with Dongwha Pharm joining as a strategic investor to drive development and commercialization of digital therapeutics for central nervous system (CNS) disorders.
Read more >
Asia Economy. (October 18, 2022)
HAII Expands Adoption of Alzheimer’s Diagnosis Digital Tool ‘Alzguard’
HAII is broadening the implementation of its AI-powered Alzheimer’s diagnostic app, Alzguard, in collaboration with Guro Gungdong Social Welfare Center, enhancing early detection efforts for dementia among the elderly.
Asia Economy. (June 19, 2022)
‘K-DTx’ Gains Global Attention at BioUSA
At the BioUSA 2022, South Korean digital therapeutics (K-DTx) companies like HAII and S. Alpha Therapeutics attracted significant interest by presenting their innovative solutions for Alzheimer’s diagnosis and sarcopenia treatment.
Asia Economy. (April 18, 2022)
HAII Presents Case Study on HCI-Based Digital Targeted Therapy for Mild Cognitive Impairment
announced the development of “AlzTalk 3.0,” a digital therapy for early detection and cognitive rehabilitation in patients with mild cognitive impairment, at the Korean Dementia Association’s academic conference.
Asia Economy. (February 23, 2022)
Korea Medical Institute Introduces HAII’s Mental Health Checkup Service ‘Mind Scope’
The Korea Medical Institute has introduced ‘Mind Scope’ service in collaboration with HAII, offering screening for six major mental illnesses and job stress at its seven national centers.
@Copyright 2022. All Right Reserved. Hosted by Imweb
@Copyright 2025. All Right Reserved.
